A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

BACKGROUND: This multicentre, open-label, Phase Ib/II trial evaluated the insulin-like growth factor (IGF) 1/2 neutralising antibody xentuzumab plus enzalutamide in metastatic castrate-resistant prostate cancer (mCRPC). METHODS: The trial included Phase Ib escalation and expansion parts and a random...

Descripción completa

Detalles Bibliográficos
Autores principales: Macaulay, Valentine M., Lord, Simon, Hussain, Syed, Maroto, José Pablo, Jones, Robert Hugh, Climent, Miguel Ángel, Cook, Natalie, Lin, Chia-Chi, Wang, Shian-Shiang, Bianchini, Diletta, Bailey, Mark, Schlieker, Laura, Bogenrieder, Thomas, de Bono, Johann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491782/
https://www.ncbi.nlm.nih.gov/pubmed/37537253
http://dx.doi.org/10.1038/s41416-023-02380-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491782/
https://www.ncbi.nlm.nih.gov/pubmed/37537253
http://dx.doi.org/10.1038/s41416-023-02380-1

Ejemplares similares